Grants and Contracts Details
The A4 study is to designed to test the hypothesis that solanezumab, will slow decline on a cognitive composite measure designed to be sensitive to early decline in the preclinical stages of AD. The A4-Tau study will evaluate whether treatment with an anti-amyloid therapy will slow increase in tau deposition over time, as measure by sequential PET scans of 18F-AV-1451, in subjects with preclinical AD in the A4 trial.
|Effective start/end date||11/1/15 → 7/21/22|
- University of Southern California: $24,500.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.